Show simple item record

dc.contributor.authorBatzloff, Michaelen_US
dc.contributor.authorChanga, Cindyen_US
dc.contributor.authorFana, Yuanyuanen_US
dc.contributor.authorGood, Michaelen_US
dc.contributor.authorH.L. Luaa, Lindaen_US
dc.contributor.authorMagor, Grahamen_US
dc.contributor.authorP. Chuana, Yapen_US
dc.contributor.authorP.J. Middelberga, Antonen_US
dc.contributor.authorRivera-Hernandeza, Taniaen_US
dc.contributor.authorWibowoa, Nanien_US
dc.date.accessioned2017-04-04T17:15:27Z
dc.date.available2017-04-04T17:15:27Z
dc.date.issued2011en_US
dc.date.modified2012-03-21T23:15:02Z
dc.identifier.issn1873-2518en_US
dc.identifier.doi10.1016/j.vaccine.2011.05.075en_US
dc.identifier.urihttp://hdl.handle.net/10072/43770
dc.description.abstractStudies on a platform technology able to deliver low-cost viral capsomeres and virus-like particles are described. The technology involves expression of the VP1 structural protein from murine polyomavirus (MuPyV) in Escherichia coli, followed by purification using scaleable units and optional cell-free VLP assembly. Two insertion sites on the surface of MuPyV VP1 are exploited for the presentation of the M2e antigen from influenza and the J8 peptide from Group A Streptococcus (GAS). Results from testing on mice following subcutaneous administration demonstrate that VLPs are self adjuvating, that adding adjuvant to VLPs provides no significant benefit in terms of antibody titre, and that adjuvanted capsomeres induce an antibody titre comparable to VLPs but superior to unadjuvanted capsomere formulations. Antibodies raised against GAS J8 peptide following immunization with chimeric J8-VP1 VLPs are bactericidal against a GAS reference strain. E. coli is easily and widely cultivated, and well understood, and delivers unparalleled volumetric productivity in industrial bioreactors. Indeed, recent results demonstrate that MuPyV VP1 can be produced in bioreactors at multi-gram-per-litre levels. The platform technology described here therefore has the potential to deliver safe and efficacious vaccine, quickly and cost effectively, at distributed manufacturing sites including those in less developed countries. Additionally, the unique advantages of VLPs including their stability on freeze drying, and the potential for intradermal and intranasal administration, suggest this technology may be suited to numerous diseases where adequate response requires large-scale and low-cost vaccine manufacture, in a way that is rapidly adaptable to temporal or geographical variation in pathogen molecular composition.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.publisherElsevieren_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom7154en_US
dc.relation.ispartofpageto7162en_US
dc.relation.ispartofissue41en_US
dc.relation.ispartofjournalVaccineen_US
dc.relation.ispartofvolume29en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchInfectious Agentsen_US
dc.subject.fieldofresearchcode060502en_US
dc.titleA microbial platform for rapid and low-cost virus-like particle and capsomere vaccinesen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2011
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record